Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANFLU-2: High-Dose vs Standard-Dose Influenza Vaccine
NCT05517174Phase 4Completed
- Start
- Sep 2022
- Primary completion
- May 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of Efluelda in influenza. Started Sep 2022; status: completed.
02
Drugs
Efluelda
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05517174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517174.